DK0978285T3 - Stabilt farmaceutisk præparat af hedgehogproteiner og anvendelse deraf - Google Patents

Stabilt farmaceutisk præparat af hedgehogproteiner og anvendelse deraf

Info

Publication number
DK0978285T3
DK0978285T3 DK99115245T DK99115245T DK0978285T3 DK 0978285 T3 DK0978285 T3 DK 0978285T3 DK 99115245 T DK99115245 T DK 99115245T DK 99115245 T DK99115245 T DK 99115245T DK 0978285 T3 DK0978285 T3 DK 0978285T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
stable pharmaceutical
hedgehog proteins
ions
hedgehog
Prior art date
Application number
DK99115245T
Other languages
Danish (da)
English (en)
Inventor
Apollon Papadimitriou
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98114851A external-priority patent/EP0987028A1/de
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of DK0978285T3 publication Critical patent/DK0978285T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK99115245T 1998-08-07 1999-08-02 Stabilt farmaceutisk præparat af hedgehogproteiner og anvendelse deraf DK0978285T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98114851A EP0987028A1 (de) 1998-08-07 1998-08-07 Pharmazeutische Zusammensetzung von Hedgehog-Proteinen und deren Verwendung
EP98116734 1998-09-03

Publications (1)

Publication Number Publication Date
DK0978285T3 true DK0978285T3 (da) 2006-03-27

Family

ID=26149508

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99115245T DK0978285T3 (da) 1998-08-07 1999-08-02 Stabilt farmaceutisk præparat af hedgehogproteiner og anvendelse deraf

Country Status (15)

Country Link
US (1) US6207718B1 (ja)
EP (1) EP0978285B1 (ja)
JP (1) JP3567103B2 (ja)
CN (1) CN1244429A (ja)
AT (1) ATE310531T1 (ja)
AU (1) AU761341B2 (ja)
CA (1) CA2279743C (ja)
DE (1) DE69928472T2 (ja)
DK (1) DK0978285T3 (ja)
ES (1) ES2253851T3 (ja)
HK (1) HK1025740A1 (ja)
HU (1) HUP9902655A3 (ja)
IL (1) IL131238A (ja)
MA (1) MA26667A1 (ja)
NO (1) NO993804L (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2312009A1 (en) * 1997-11-28 1999-06-10 Roche Diagnostics Gmbh An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
US6897297B1 (en) * 1997-12-03 2005-05-24 Curis, Inc. Hydrophobically-modified protein compositions and methods
EP1557427A3 (en) * 1998-04-30 2005-10-19 Curis, Inc. Hedgehog protein conjugate
EP1025861A1 (de) * 1999-02-04 2000-08-09 Roche Diagnostics GmbH Pharmazeutische Zusammensetzung von hydrophob modifizierten Hedgehog-Proteinen und deren Verwendung
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
CA2280925A1 (en) * 1999-07-29 2001-01-29 Bernard Charles Sherman Stabilized cefuroxime axetil
WO2001082994A1 (en) * 2000-04-28 2001-11-08 Curis, Inc. Methods and reagents for tissue engineering of cartilage in vitro
EP1947116B1 (en) 2003-02-10 2017-06-21 2-BBB Medicines B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
US20070053883A1 (en) * 2003-03-25 2007-03-08 The Johns Hopkins University Neuronal cell lineages and methods of production thereof
US20070148144A1 (en) * 2005-10-27 2007-06-28 Mason James M Gene-enhanced tissue engineering
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
EP2125024B1 (en) 2007-03-23 2013-02-13 TO-BBB Holding B.V. Targeted intracellular delivery of antiviral agents
WO2009006097A1 (en) * 2007-06-29 2009-01-08 Johnson & Johnson Regenerative Therapeutics, Llc Liquid protein formulations comprising gdf-5 for use at elevated temperatures
US7678764B2 (en) * 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
JP5323832B2 (ja) * 2007-08-07 2013-10-23 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 酸性水溶液中にｇｄｆ−５を含むタンパク質製剤
US7947649B2 (en) * 2008-04-14 2011-05-24 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered GDF-5 formulations
WO2010087702A1 (en) 2009-01-30 2010-08-05 Stichting Katholieke Universiteit TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
EP2478101A1 (en) 2009-09-16 2012-07-25 Stichting Het Nederlands Kanker Instituut Fra-1 target genes as drug targets for treating cancer
EP2305717A1 (en) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Inhibiting TNIK for treating colon cancer
WO2012026820A2 (en) 2010-08-27 2012-03-01 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
EP2465928A1 (en) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Treatment of Th17-mediated diseases
US11633458B2 (en) 2013-11-08 2023-04-25 University Of Virginia Patent Foundation Compositions and methods for treating melanoma
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
CN110248648B (zh) * 2016-11-16 2023-02-24 艾维塔生物医学公司 细胞膜结合信号因子的应用
CN111356447B (zh) * 2017-11-16 2023-03-24 艾维塔生物医学公司 细胞膜结合信号传导因子的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148901A (en) 1983-10-04 1985-06-05 Johnson & Johnson Protein/polysaccharide complexes
JPH0725689B2 (ja) 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5156623A (en) 1990-04-16 1992-10-20 Olympus Optical Co., Ltd. Sustained release material and method of manufacturing the same
US5416071A (en) 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5789543A (en) 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
WO1995018856A1 (en) * 1993-12-30 1995-07-13 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing hedgehog-like proteins
JPH09509574A (ja) 1994-02-25 1997-09-30 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 脊索によって発現されるヘッジホッグ、Ｖｈｈ−１、の脊椎動物相同体をコードするＤＮＡ、及びこれらの使用
US5663390A (en) 1996-08-29 1997-09-02 Libbey-Owens-Ford Co. Method of producing organo indium chlorides
JPH10194987A (ja) * 1997-01-14 1998-07-28 Youtai Iwamoto 骨・軟骨形成用組成物
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
EP0947201B1 (en) 1998-02-04 2006-06-28 Curis, Inc. Pharmaceutical composition of hedgehog proteins and use thereof
EP0953575A1 (de) 1998-04-30 1999-11-03 Boehringer Mannheim Gmbh Aktives Hedgehog-Protein-Konjugat, Verfahren zur Herstellung und Verwendung
EP1557427A3 (en) 1998-04-30 2005-10-19 Curis, Inc. Hedgehog protein conjugate

Also Published As

Publication number Publication date
DE69928472T2 (de) 2006-08-10
HK1025740A1 (en) 2000-11-24
EP0978285A1 (en) 2000-02-09
NO993804L (no) 2000-02-08
JP3567103B2 (ja) 2004-09-22
IL131238A (en) 2005-07-25
AU4344899A (en) 2000-03-02
MA26667A1 (fr) 2004-12-20
DE69928472D1 (de) 2005-12-29
HUP9902655A3 (en) 2000-12-28
CN1244429A (zh) 2000-02-16
AU761341B2 (en) 2003-06-05
US6207718B1 (en) 2001-03-27
CA2279743A1 (en) 2000-02-07
ES2253851T3 (es) 2006-06-01
HU9902655D0 (en) 1999-10-28
NO993804D0 (no) 1999-08-06
IL131238A0 (en) 2001-01-28
ATE310531T1 (de) 2005-12-15
HUP9902655A2 (hu) 2000-08-28
JP2000063283A (ja) 2000-02-29
CA2279743C (en) 2005-05-10
EP0978285B1 (en) 2005-11-23

Similar Documents

Publication Publication Date Title
DK0978285T3 (da) Stabilt farmaceutisk præparat af hedgehogproteiner og anvendelse deraf
DE60103351D1 (de) Zusammensetzung zur Bekämpfung von Ektoparasiten
DE69924232D1 (de) Stabilisierte insulin-zubereitungen
PT953335E (pt) Composicao solida desodorizante
DE69838130D1 (de) Riechstoffzusammensetzungen
DE69939661D1 (de) Hautdesodorierende und desinfizierende zubereitung
RS50071B (sr) Novi oblik soli pantoprazola
EA199900373A2 (ru) Фармацевтические композиции
BR9915515B1 (pt) composiÇço curÁvel de multicomponentes.
BR9909831B1 (pt) composiÇço dental de dois componentes.
ATE376996T1 (de) Antibakterielle mittel
DE69920730D1 (de) Wässrige zusammensetzung
PT1250321E (pt) Composicao de gliburida
PT1100326E (pt) Microcapsulas de libertacao activada por bases
DK0986620T3 (da) Sammensætning af støvkontrol
ATE335499T1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
BR9910539A (pt) Derivados de 2 - (2 - clorofenil) - 3,4 - dihidro - 2h - pirrol
BR9907304B1 (pt) refratÁrio de alumina-magnÉsia-grafita.
TR199903132A3 (tr) Metalosan bilesiklerinin aktive edici kompozisyonu.
ATE306246T1 (de) Zahnputzzusammensetzung
MXPA03001802A (es) Composicion acondicionadora pre-champu.
DE69936052D1 (de) N1 modifizierte glycopeptide
BR9916537B1 (pt) composição de fragráncia, e, produto.
BR0009469A (pt) Tablete perfumado de detergente
AU2001265876A1 (en) Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases